Roivant Sciences Ltd. (FRA:87S)
Germany · Delayed Price · Currency is EUR | Market Cap | 22.57B +225.2% |
| Revenue (ttm) | 6.59M -67.6% |
| Net Income | -233.05M |
| EPS | -0.43 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 30.91 |
| Previous Close | 30.83 |
| Day's Range | 30.82 - 30.92 |
| 52-Week Range | 9.73 - 32.21 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Roivant Sciences
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rh... [Read more]
Financial Performance
In fiscal year 2026, Roivant Sciences's revenue was $8.26 million, a decrease of -71.57% compared to the previous year's $29.05 million. Losses were -$299.77 million, 74.3% more than in 2025.
Financial numbers in USD Financial StatementsNews
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
DURHAM, N.C., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitini...
Roivant Sciences price target raised to $37 from $35 at BofA
BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $37 from $35 and keeps a Neutral rating on the shares. The firm adjusted targets for…
Roivant Sciences price target raised to $46 from $42 at Citi
Citi raised the firm’s price target on Roivant Sciences (ROIV) to $46 from $42 and keeps a Buy rating on the shares.
Roivant Sciences price target raised to $42 from $36 at Guggenheim
Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $42 from $36 and keeps a Buy rating on the shares.
Roivant Sciences price target raised to $41 from $34 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $34 and keeps a Buy rating on the shares. The firm says the…
TD Cowen boosts Roivant Sciences price target, says has many catalysts on deck
TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $50 from $41 and keeps a Buy rating on the shares following Q1 results. The firm noted Roivant…
Roivant Sciences Earnings Call Transcript: Q1 2027
Pipeline progress continues with imminent DM launch, strong cash position, and $950M from Moderna settlement. Multiple clinical readouts and launches expected in the next 18 months, with a focus on building a robust commercial foundation and ongoing capital returns.
Roivant Sciences Quarterly report: Q1 2027
Roivant Sciences has published its Q1 2027 quarterly earnings report on August 6, 2026.
Roivant Sciences Slides: Q1 2027
Roivant Sciences has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 6, 2026.
Roivant Sciences Earnings release: Q1 2027
Roivant Sciences released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
Roivant Sciences reports Q1 EPS (26c), consensus (36c)
Reports Q1 revenue $1.44M, consensus $2.34M. “This quarter has been a moment of relative quiet between our incredibly busy last twelve months and our even busier year ahead,” said Matt…
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (N...
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (P...
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), diffi...
Roivant Sciences price target raised to $35 from $31.50 at BofA
BofA raised the firm’s price target on Roivant Sciences (ROIV) to $35 from $31.50 and keeps a Neutral rating on the shares. The firm sees balanced risk/reward into Roivant’s Phase…
Roivant Sciences Proxy statement: Proxy filing
Roivant Sciences filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
Roivant Sciences Proxy statement: Proxy filing
Roivant Sciences filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, A...
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August ...
Arbutus initiates patent infringement actions against Pfizer, BioNTech
Arbutus Biopharma (ABUS) and its exclusive licensee, Genevant Sciences, a subsidiary of Roivant (ROIV), announced the filing of three international lawsuits seeking to enforce patents protecting their...
Roivant Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The portfolio model remains central, supporting strong execution and asset selection. Brepocitinib leads the pipeline with a 2026 PDUFA date and expansion into multiple orphan indications. Robust clinical data, strategic pricing, and a well-capitalized position underpin plans for launches and further business development.
Roivant Sciences Transcript: Jefferies Global Healthcare Conference 2026
Significant late-stage pipeline progress includes an imminent DM launch and upcoming data for NIU and PH-ILD. Commercial strategy leverages rare disease launch experience, with pricing expected at the lower end of the range. Multiple catalysts and expansion opportunities are anticipated in the second half of the year.
Roivant Sciences Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Revised summary: The discussion highlighted a differentiated asset acquisition and clinical development model, with a robust pipeline targeting unmet needs in orphan and autoimmune diseases. Key launches, especially brepocitinib, are expected to drive growth, supported by capital efficiency and AI-driven trial operations.
Roivant Sciences price target raised to $40 from $35 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Roivant Sciences (ROIV) to $40 from $35 and keeps an Overweight rating on the shares. The firm updated the company’s…
Roivant Sciences price target raised to $36 from $30 at Guggenheim
Guggenheim analyst Yastin Suneja raised the firm’s price target on Roivant Sciences (ROIV) to $36 from $30 and keeps a Buy rating on the shares. The firm updated its model…